The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study.
acute toxicity
gastrointestinal
genitourinary
intensity-modulated radiotherapy
late toxicity
prostate cancer
stereotactic body radiotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Feb 2023
17 Feb 2023
Historique:
received:
19
01
2023
revised:
10
02
2023
accepted:
11
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Several studies have demonstrated the association between acute and late radiotherapy toxicity in prostate cancer using older radiotherapy techniques. However, whether this association is present with newer techniques such as stereotactic body radiotherapy (SBRT), remains unclear. We use univariable and multivariable logistic regression to analyse the association between grade 2 or worse acute gastrointestinal (GI) and genitourinary (GU) toxicities with equivalent late toxicities in patients treated with SBRT and conventional or moderately fractionated radiotherapy (CRT) within the PACE-B study. 842 patients were included in this analysis. Common Terminology Criteria for Adverse Events (CTCAE) was the primary clinician reported outcome measure used in this analysis. In univariable analysis, experiencing a grade 2+ acute GU toxicity was significantly associated with developing a grade 2+ late GU toxicity after SBRT (OR 4.63, 95% CI (2.96-7.25),
Identifiants
pubmed: 36831631
pii: cancers15041288
doi: 10.3390/cancers15041288
pmc: PMC9954684
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : R.R is a clinical research fellow supported by Institutional funding from Accuray
ID : n/a
Références
Cancers (Basel). 2022 Mar 25;14(7):
pubmed: 35406443
Frontline Gastroenterol. 2015 Jan;6(1):53-72
pubmed: 25580207
Urology. 2015 Jan;85(1):101-5
pubmed: 25530370
Lancet Oncol. 2022 Oct;23(10):1308-1320
pubmed: 36113498
Radiat Oncol. 2010 Apr 08;5:27
pubmed: 20377874
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1013-21
pubmed: 20447774
J Urol. 1992 Nov;148(5):1549-57; discussion 1564
pubmed: 1279218
Lancet Oncol. 2007 Nov;8(11):1007-17
pubmed: 17976611
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1124-9
pubmed: 18313526
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Stat Med. 1997 Feb 28;16(4):385-95
pubmed: 9044528
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
CA Cancer J Clin. 2021 Sep;71(5):437-454
pubmed: 34255347
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Acta Oncol. 2012 Nov;51(8):963-74
pubmed: 22966812
Support Care Cancer. 2016 Aug;24(8):3669-76
pubmed: 27260018
Radiother Oncol. 2001 Dec;61(3):223-31
pubmed: 11730991
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Prostate Cancer. 2015;2015:624736
pubmed: 26697225
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):26-34
pubmed: 20133085
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Strahlenther Onkol. 2019 May;195(5):393-401
pubmed: 30406289
Lancet Oncol. 2019 Nov;20(11):1531-1543
pubmed: 31540791
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):442-9
pubmed: 12243820
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):89-94
pubmed: 22652106
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):3-10
pubmed: 16814954
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757